PHAXIAM Therapeutics S.A. (LON:0QSS)
1.884
0.00 (0.00%)
At close: Feb 21, 2025
PHAXIAM Therapeutics Revenue
PHAXIAM Therapeutics had revenue of 546.50K EUR in the quarter ending June 30, 2024, with 293.17% growth. This brings the company's revenue in the last twelve months to 2.14M, down -64.15% year-over-year. In the year 2023, PHAXIAM Therapeutics had annual revenue of 1.33M, down -80.05%.
Revenue (ttm)
2.14M EUR
Revenue Growth
-64.15%
P/S Ratio
n/a
Revenue / Employee
31.49K EUR
Employees
68
Market Cap
15.73M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.33M | -5.32M | -80.05% |
Dec 31, 2022 | 6.65M | 2.47M | 59.02% |
Dec 31, 2021 | 4.18M | 462.00K | 12.43% |
Dec 31, 2020 | 3.72M | -1.57M | -29.62% |
Dec 31, 2019 | 5.28M | 836.00K | 18.80% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Genus | 668.80M |
PHAXIAM Therapeutics News
- 3 months ago - PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area - GlobeNewsWire
- 3 months ago - PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" - GlobeNewsWire
- 3 months ago - PHAXIAM Reports Third-Quarter 2024 Financial Information - GlobeNewsWire
- 3 months ago - PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S. - GlobeNewsWire
- 5 months ago - PHAXIAM Provides Business and Financial Update For the First Half of 2024 - GlobeNewsWire
- 8 months ago - Results of the Combined General Meeting of 28 June 2024 - GlobeNewsWire
- 9 months ago - PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024 - GlobeNewsWire
- 10 months ago - PHAXIAM provides Business and Financial Update for the First Quarter of 2024 - GlobeNewsWire